Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$0.18 - $3.51 $55 - $1,088
310 New
310 $0
Q3 2021

Nov 15, 2021

SELL
$3.19 - $4.43 $3,987 - $5,537
-1,250 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$3.58 - $4.9 $4,475 - $6,125
1,250 New
1,250 $6,000

Others Institutions Holding CFRX

About CONTRAFECT Corp


  • Ticker CFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,332,700
  • Market Cap $1.18M
  • Description
  • ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
More about CFRX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.